CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor

Transplantation

Volumn 101, Issue 10, 2017, Pages e315-e325

  Schachtner, Thomas ^a,b,c   Stein, Maik ^b   Reinke, Petra ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORINE; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; MYCOPHENOLATE MOFETIL; STEROID; TACROLIMUS; ANTIVIRUS AGENT; BIOLOGICAL MARKER; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CELL KINETICS; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; ADVERSE EFFECTS; ALLOGRAFT; BLOOD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DONOR; DRUG EFFECTS; GENETICS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ALLOGRAFTS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOMARKERS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEROLOGIC TESTS; T-LYMPHOCYTES; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION; YOUNG ADULT;

EID: 85020417308     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001825     Document Type: Article

References (32)

1. Green M, Avery RK, Preiksaitis J, et al. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant. 2004;4(Suppl 10):51-58.
2. Schnitzler MA, Lowell JA, Hmiel SP, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol. 2003;14:780-785.
3. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant. 2004;4:928-936.
4. Humar A, Michaels M. AST IDWorking Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262-274.
5. Yang CW, Kim YO, Kim YS, et al. Clinical course of cytomegalovirus (CMV) viremiawith and without ganciclovir treatment in CMV sero-positive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol. 1998;18:373-378.
6. Toupance O, Bouedjoro-Camus MC, Carquin J, et al. Cytomegalovirusrelated disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses. Transpl Int. 2000;13:413-419.
7. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation. 2000;70:1166-1174.
8. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751.
9. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66:329-337.
10. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002;2:850-856.
11. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid organ transplants: A systematic review of randomised controlled trials. Lancet. 2005; 365:2105.
12. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetesmellitus and impaired insulin release after renal transplantation. Diabetologia. 2004; 47:1550-1556.
13. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet. 1994;344:1737-1738.
14. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228-1237.
15. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol. 2006;16:281-287.
16. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620.
17. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reactionmonitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
18. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis. 2004;189:1355-1361.
19. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant. 2008;8:990-999.
20. Sester U, Presser D, Dirks J, et al. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 2008;8:1486-1497.
21. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med. 1995;333: 1038-1044.
22. Sacre K, Carcelain G, Cassoux N, et al. Repertoire, diversity, and differentiation of specific CD8 Tcells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005;201:1999-2010.
23. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202: 673-685.
24. Pahl-Seibert MF, Juelch M, Podlech J, et al. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol. 2005;79:5400-5413.
25. Bestard O, Lucia M, Crespo E, et al. Pretransplant immediately early-1-specific Tcell responses provide protection for CMV infection after kidney transplantation. Am J Transplant. 2013;13:1793-1805.
26. Lucia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specificmemory Tand B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis. 2014;59:1537-1545.
27. Schachtner T, Stein M, Babel N, et al. The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant. 2015;15: 2159-2169.
28. Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol. 2009;20:238-242.
29. Schachtner T, Stein M, Reinke P. ABO desensitization affects cellular immunity and infection control after renal transplantation. Transpl Int. 2015; 28:1179-1194.
30. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIGStudy Group. Cytogam, Med Immune, Inc. Gaithersburg, Maryland. Am J Med. 1997;103:106-613.
31. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201:1031-1036.
32. López-Oliva MO, Martinez V, Buitrago A, et al. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant. Transplantation. 2014;97:839-845.